38604453|t|Innovative Approaches to Alzheimer's Therapy: Harnessing the Power of Heterocycles, Oxidative Stress Management, and Nanomaterial Drug Delivery System.
38604453|a|Alzheimer's disease (AD) presents a complex pathology involving amyloidogenic proteolysis, neuroinflammation, mitochondrial dysfunction, and cholinergic deficits. Oxidative stress exacerbates AD progression through pathways like macromolecular peroxidation, mitochondrial dysfunction, and metal ion redox potential alteration linked to amyloid-beta (Abeta). Despite limited approved medications, heterocyclic compounds have emerged as promising candidates in AD drug discovery. This review highlights recent advancements in synthetic heterocyclic compounds targeting oxidative stress, mitochondrial dysfunction, and neuroinflammation in AD. Additionally, it explores the potential of nanomaterial-based drug delivery systems to overcome challenges in AD treatment. Nanoparticles with heterocyclic scaffolds, like polysorbate 80-coated PLGA and Resveratrol-loaded nano-selenium, show improved brain transport and efficacy. Micellar CAPE and Melatonin-loaded nano-capsules exhibit enhanced antioxidant properties, while a tetra hydroacridine derivative (CHDA) combined with nano-radiogold particles demonstrates promising acetylcholinesterase inhibition without toxicity. This comprehensive review underscores the potential of nanotechnology-driven drug delivery for optimizing the therapeutic outcomes of novel synthetic heterocyclic compounds in AD management. Furthermore, the inclusion of various promising heterocyclic compounds with detailed ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) data provides valuable insights for planning the development of novel drug delivery treatments for AD.
38604453	25	36	Alzheimer's	Disease	MESH:D000544
38604453	152	171	Alzheimer's disease	Disease	MESH:D000544
38604453	173	175	AD	Disease	MESH:D000544
38604453	243	260	neuroinflammation	Disease	MESH:D000090862
38604453	262	287	mitochondrial dysfunction	Disease	MESH:D028361
38604453	293	313	cholinergic deficits	Disease	MESH:C535672
38604453	344	346	AD	Disease	MESH:D000544
38604453	410	435	mitochondrial dysfunction	Disease	MESH:D028361
38604453	441	446	metal	Chemical	MESH:D008670
38604453	488	500	amyloid-beta	Gene	351
38604453	502	507	Abeta	Gene	351
38604453	548	570	heterocyclic compounds	Chemical	MESH:D006571
38604453	611	613	AD	Disease	MESH:D000544
38604453	686	708	heterocyclic compounds	Chemical	MESH:D006571
38604453	737	762	mitochondrial dysfunction	Disease	MESH:D028361
38604453	768	785	neuroinflammation	Disease	MESH:D000090862
38604453	789	791	AD	Disease	MESH:D000544
38604453	903	905	AD	Disease	MESH:D000544
38604453	965	979	polysorbate 80	Chemical	MESH:D011136
38604453	987	991	PLGA	Chemical	MESH:D000077182
38604453	996	1007	Resveratrol	Chemical	MESH:D000077185
38604453	1020	1028	selenium	Chemical	MESH:D012643
38604453	1092	1101	Melatonin	Chemical	MESH:D008550
38604453	1178	1191	hydroacridine	Chemical	-
38604453	1204	1208	CHDA	Chemical	-
38604453	1272	1292	acetylcholinesterase	Gene	43
38604453	1312	1320	toxicity	Disease	MESH:D064420
38604453	1472	1494	heterocyclic compounds	Chemical	MESH:D006571
38604453	1498	1500	AD	Disease	MESH:D000544
38604453	1561	1583	heterocyclic compounds	Chemical	MESH:D006571
38604453	1658	1666	Toxicity	Disease	MESH:D064420
38604453	1767	1769	AD	Disease	MESH:D000544
38604453	Association	MESH:D008670	351
38604453	Negative_Correlation	MESH:D006571	MESH:D000544
38604453	Association	MESH:D000544	351
38604453	Association	MESH:D000077182	MESH:D011136
38604453	Negative_Correlation	MESH:D006571	MESH:D028361
38604453	Negative_Correlation	MESH:D006571	MESH:D000090862
38604453	Association	MESH:D000077185	MESH:D012643

